Sachin Patel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1462331/publications.pdf

Version: 2024-02-01

80 papers 6,001 citations

39 h-index 74163 75 g-index

84 all docs 84 docs citations

times ranked

84

4786 citing authors

#	Article	IF	CITATIONS
1	Characterizing the transcriptionallyâ€activated ensembles recruited by cocaine in the nucleus accumbens. FASEB Journal, 2022, 36, .	0.5	O
2	The Endocannabinoid 2-Arachidonoylglycerol Bidirectionally Modulates Acute and Protracted Effects of Predator Odor Exposure. Biological Psychiatry, 2022, 92, 739-749.	1.3	6
3	Impact of cyclooxygenaseâ€2 inhibition on cannabis withdrawal and circulating endocannabinoids in daily cannabis smokers. Addiction Biology, 2022, 27, .	2.6	4
4	The endocannabinoid system in humans: significant associations between anandamide, brain function during reward feedback and a personality measure of reward dependence. Neuropsychopharmacology, 2021, 46, 1020-1027.	5.4	5
5	Cannabis use and posttraumatic stress disorder comorbidity: Epidemiology, biology and the potential for novel treatment approaches. International Review of Neurobiology, 2021, 157, 143-193.	2.0	10
6	InÂvivo endocannabinoid dynamics at the timescale of physiological and pathological neural activity. Neuron, 2021, 109, 2398-2403.e4.	8.1	38
7	Cocaine restricts nucleus accumbens feedforward drive through a monoamine-independent mechanism. Neuropsychopharmacology, 2021, , .	5.4	2
8	CaMKII Modulates Diacylglycerol Lipase- \hat{l}_{\pm} Activity in the Rat Nucleus Accumbens after Incubation of Cocaine Craving. ENeuro, 2021, 8, ENEURO.0220-21.2021.	1.9	5
9	Targeting diacylglycerol lipase reduces alcohol consumption in preclinical models. Journal of Clinical Investigation, 2021, 131, .	8.2	13
10	Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	7.1	0
11	Endogenous cannabinoids are required for MC4R-mediated control of energy homeostasis. Proceedings of the National Academy of Sciences of the United States of America, 2021, $118,\ldots$	7.1	6
12	Endocannabinoid signaling and stress resilience. , 2020, , 349-362.		O
13	Cyclooxygenase-2 inhibition prevents stress induced amygdala activation and anxiety-like behavior. Brain, Behavior, and Immunity, 2020, 89, 513-517.	4.1	8
14	"Corting―stress: post-stress corticosterone administration prevents delayed-onset biobehavioral consequences. Neuropsychopharmacology, 2020, 45, 2135-2136.	5.4	3
15	Arrested Development: A Story of How Perinatal Cannabinoids Affect the Maturation of the Prefrontal Cortex. Biological Psychiatry, 2020, 87, 595-596.	1.3	O
16	α2A-adrenergic heteroreceptors are required for stress-induced reinstatement of cocaine conditioned place preference. Neuropsychopharmacology, 2020, 45, 1473-1481.	5.4	8
17	Endocannabinoid Signaling Collapse Mediates Stress-Induced Amygdalo-Cortical Strengthening. Neuron, 2020, 105, 1062-1076.e6.	8.1	62
18	2-Arachidonoylglycerol Modulation of Anxiety and Stress Adaptation: From Grass Roots to Novel Therapeutics. Biological Psychiatry, 2020, 88, 520-530.	1.3	36

#	Article	IF	Citations
19	An endocannabinoid-regulated basolateral amygdala–nucleus accumbens circuit modulates sociability. Journal of Clinical Investigation, 2020, 130, 1728-1742.	8.2	7 2
20	Endocannabinoid Signaling in the Central Amygdala and Bed Nucleus of the Stria Terminalis: Implications for the Pathophysiology and Treatment of Alcohol Use Disorder. Alcoholism: Clinical and Experimental Research, 2019, 43, 2014-2027.	2.4	16
21	Dynamic remodeling of a basolateral-to-central amygdala glutamatergic circuit across fear states. Nature Neuroscience, 2019, 22, 2000-2012.	14.8	45
22	Cyclooxygenase-2 inhibition reduces anxiety-like behavior and normalizes enhanced amygdala glutamatergic transmission following chronic oral corticosterone treatment. Neurobiology of Stress, 2019, 11, 100190.	4.0	19
23	Driving the Downward Spiral: Alcoholâ€Induced Dysregulation of Extended Amygdala Circuits and Negative Affect. Alcoholism: Clinical and Experimental Research, 2019, 43, 2000-2013.	2.4	37
24	Leptin Receptor Signaling in Sim1-Expressing Neurons Regulates Body Temperature and Adaptive Thermogenesis. Endocrinology, 2019, 160, 863-879.	2.8	12
25	The association between endogenous opioid function and morphine responsiveness: a moderating role for endocannabinoids. Pain, 2019, 160, 676-687.	4.2	12
26	Endocannabinoid control of the insular-bed nucleus of the stria terminalis circuit regulates negative affective behavior associated with alcohol abstinence. Neuropsychopharmacology, 2019, 44, 526-537.	5.4	68
27	Aspects of Prostaglandin Glycerol Ester Biology. Advances in Experimental Medicine and Biology, 2019, 1161, 77-88.	1.6	12
28	Cocaine-induced endocannabinoid signaling mediated by sigma-1 receptors and extracellular vesicle secretion. ELife, $2019,8,.$	6.0	36
29	Phasic Dopamine Signals in the Nucleus Accumbens that Cause Active Avoidance Require Endocannabinoid Mobilization in the Midbrain. Current Biology, 2018, 28, 1392-1404.e5.	3.9	64
30	Role of Striatal Direct Pathway 2-Arachidonoylglycerol Signaling in Sociability and Repetitive Behavior. Biological Psychiatry, 2018, 84, 304-315.	1.3	36
31	Detection of Cyclooxygenase-2-Derived Oxygenation Products of the Endogenous Cannabinoid 2-Arachidonoylglycerol in Mouse Brain. ACS Chemical Neuroscience, 2018, 9, 1552-1559.	3.5	28
32	Therapeutic endocannabinoid augmentation for mood and anxiety disorders: comparative profiling of FAAH, MAGL and dual inhibitors. Translational Psychiatry, 2018, 8, 92.	4.8	76
33	Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder. Neuropsychopharmacology, 2018, 43, 80-102.	5.4	170
34	Inhibition of Diacylglycerol Lipase Impairs Fear Extinction in Mice. Frontiers in Neuroscience, 2018, 12, 479.	2.8	32
35	The endocannabinoid system as a target for novel anxiolytic drugs. Neuroscience and Biobehavioral Reviews, 2017, 76, 56-66.	6.1	182
36	Endocannabinoid signalling modulates susceptibility to traumatic stress exposure. Nature Communications, 2017, 8, 14782.	12.8	108

#	Article	IF	Citations
37	Functional Redundancy Between Canonical Endocannabinoid Signaling Systems in the Modulation of Anxiety. Biological Psychiatry, 2017, 82, 488-499.	1.3	81
38	A Guide to the National Academy of Science Report on Cannabis: An Exclusive Discussion with Panel Members. Cannabis and Cannabinoid Research, 2017, 2, 155-159.	2.9	8
39	Cyclooxygenase-2 inhibition reduces stress-induced affective pathology. ELife, 2016, 5, .	6.0	45
40	Electrophysiological Measurement of Cannabinoidâ€Mediated Synaptic Modulation in Acute Mouse Brain Slices. Current Protocols in Neuroscience, 2016, 75, 6.29.1-6.29.19.	2.6	9
41	Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release. Neuron, 2016, 91, 1244-1252.	8.1	110
42	Acute and chronic ethanol exposure differentially regulate CB1 receptor function at glutamatergic synapses in the rat basolateral amygdala. Neuropharmacology, 2016, 108, 474-484.	4.1	22
43	Neurobiological Interactions Between Stress and the Endocannabinoid System. Neuropsychopharmacology, 2016, 41, 80-102.	5.4	453
44	Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology, 2016, 66, 151-158.	2.7	47
45	Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking. Neuropsychopharmacology, 2016, 41, 2062-2071.	5.4	70
46	Fluoxetine Facilitates Fear Extinction Through Amygdala Endocannabinoids. Neuropsychopharmacology, 2016, 41, 1598-1609.	5.4	37
47	The Anxiolytic Actions of 2-Arachidonoylglycerol: Converging Evidence From Two Recent Genetic Endocannabinoid Deficiency Models. Biological Psychiatry, 2016, 79, e78-e79.	1.3	7
48	A cellular basis for the munchies. Nature, 2015, 519, 38-40.	27.8	7
49	Corticotropin-Releasing Hormone Drives Anandamide Hydrolysis in the Amygdala to Promote Anxiety. Journal of Neuroscience, 2015, 35, 3879-3892.	3.6	196
50	Prefrontal inputs to the amygdala instruct fear extinction memory formation. Science Advances, 2015, $1, \dots$	10.3	181
51	The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. Neuropharmacology, 2015, 91, 57-62.	4.1	23
52	The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival, attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Neuropharmacology, 2014, 85, 427-439.	4.1	82
53	Genetic Disruption of 2-Arachidonoylglycerol Synthesis Reveals a Key Role for Endocannabinoid Signaling in Anxiety Modulation. Cell Reports, 2014, 9, 1644-1653.	6.4	135
54	Multiple Mechanistically Distinct Modes of Endocannabinoid Mobilization at Central Amygdala Glutamatergic Synapses. Neuron, 2014, 81, 1111-1125.	8.1	69

#	Article	IF	Citations
55	Substrate-selective COX-2 inhibition as a novel strategy for therapeutic endocannabinoid augmentation. Trends in Pharmacological Sciences, 2014, 35, 358-367.	8.7	95
56	Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nature Neuroscience, 2013, 16, 1291-1298.	14.8	109
57	Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology, 2013, 228, 401-409.	3.1	31
58	Translational evidence for the involvement of the endocannabinoid system in stress-related psychiatric illnesses. Biology of Mood & Anxiety Disorders, 2013, 3, 19.	4.7	84
59	CaMKII regulates diacylglycerol lipase-α and striatal endocannabinoid signaling. Nature Neuroscience, 2013, 16, 456-463.	14.8	65
60	High Times for Low-Frequency Stimulation as Endocannabinoids Engage in Hippocampal Long-Term Depression. Neuropsychopharmacology, 2012, 37, 583-585.	5.4	2
61	Reversible Gating of Endocannabinoid Plasticity in the Amygdala by Chronic Stress: A Potential Role for Monoacylglycerol Lipase Inhibition in the Prevention of Stress-Induced Behavioral Adaptation. Neuropsychopharmacology, 2011, 36, 2750-2761.	5.4	110
62	Functional Interactions between Stress and the Endocannabinoid System: From Synaptic Signaling to Behavioral Output. Journal of Neuroscience, 2010, 30, 14980-14986.	3.6	202
63	An Odyssey of Fear: Homer Stresses New Mechanisms. Biological Psychiatry, 2010, 68, 980-981.	1.3	1
64	Repeated Homotypic Stress Elevates 2-Arachidonoylglycerol Levels and Enhances Short-Term Endocannabinoid Signaling at Inhibitory Synapses in Basolateral Amygdala. Neuropsychopharmacology, 2009, 34, 2699-2709.	5.4	133
65	The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants. Trends in Pharmacological Sciences, 2009, 30, 484-493.	8.7	147
66	Role of Endocannabinoid Signaling in Anxiety and Depression. Current Topics in Behavioral Neurosciences, 2009, 1, 347-371.	1.7	48
67	Prolonged glucocorticoid treatment decreases cannabinoid CB ₁ receptor density in the hippocampus. Hippocampus, 2008, 18, 221-226.	1.9	86
68	Adaptations in endocannabinoid signaling in response to repeated homotypic stress: a novel mechanism for stress habituation. European Journal of Neuroscience, 2008, 27, 2821-2829.	2.6	139
69	Ritualistic excoriation and blood-letting resulting in anemia in borderline personality disorder. General Hospital Psychiatry, 2006, 28, 539-540.	2.4	2
70	Pharmacological Evaluation of Cannabinoid Receptor Ligands in a Mouse Model of Anxiety: Further Evidence for an Anxiolytic Role for Endogenous Cannabinoid Signaling. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 304-311.	2.5	342
71	Inhibition of restraint stress-induced neural and behavioural activation by endogenous cannabinoid signalling. European Journal of Neuroscience, 2005, 21, 1057-1069.	2.6	260
72	Downregulation of Endocannabinoid Signaling in the Hippocampus Following Chronic Unpredictable Stress. Neuropsychopharmacology, 2005, 30, 508-515.	5.4	313

SACHIN PATEL

#	Article	IF	CITATION
73	The postmortal accumulation of brain N-arachidonylethanolamine (anandamide) is dependent upon fatty acid amide hydrolase activity. Journal of Lipid Research, 2005, 46, 342-349.	4.2	114
74	Synergistic Interactions between Cannabinoids and Environmental Stress in the Activation of the Central Amygdala. Neuropsychopharmacology, 2005, 30, 497-507.	5.4	148
75	Endocannabinoid Signaling Negatively Modulates Stress-Induced Activation of the Hypothalamic-Pituitary-Adrenal Axis. Endocrinology, 2004, 145, 5431-5438.	2.8	412
76	Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Research, 2003, 963, 15-25.	2.2	63
77	The general anesthetic propofol increases brain N -arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. British Journal of Pharmacology, 2003, 139, 1005-1013.	5.4	123
78	Differential Regulation of the Endocannabinoids Anandamide and 2-Arachidonylglycerol within the Limbic Forebrain by Dopamine Receptor Activity. Journal of Pharmacology and Experimental Therapeutics, 2003, 306, 880-888.	2.5	144
79	The CB1 receptor antagonist SR141716 enhances stimulus-induced activation of the primary somatosensory cortex of the rat. Neuroscience Letters, 2002, 335, 95-98.	2.1	14
80	Endocannabinoid Signaling Collapse Mediates Stress-Induced Amygdalo-Cortical Strengthening. SSRN Electronic Journal, 0, , .	0.4	0